February 3, 2006 – InterMune stopped a Phase III trial of its ovarian cancer drug after survival was better in the placebo cohort; GlycoGenesys filed for Chapter 11 bankruptcy, laying off half its work force; OccuLogix took a 67% hit after its blindness drug failed a Phase III trial; Myogen sold its European subsidiary and the non-US rights to a drug for $6.1 million; Tapestry Pharma sold $25.5 million of stock to investors and effected a 1-for-10 reverse split; Somaxon Pharma pointed to a journal article underscoring the efficacy of its compulsive gambling drug; Geron presented positive data from a laboratory study on its HIV/AIDS drug; and Zonagen reported positive top-line data on its oral testosterone drug, Androxal. The Centient Biotech 200™ was 13 points lower at 3938.34, a loss of .34%. More details...
